ROCKVILLE, Md.--(BUSINESS WIRE)--
BIOQUAL, Inc. (OTC Pink: BIOQ) ():
Three Months Ended
|
||||||
|
2020 |
2019 |
|
|||
|
|
|
|
|||
Revenue |
$ |
14,920,475 |
$ |
10,067,876 |
|
|
Income Before Income Tax |
$ |
2,496,988 |
$ |
1,874,483 |
|
|
Net Income |
$ |
1,766,588 |
$ |
1,324,483 |
|
|
Basic Earnings per Share |
|
|
|
|
|
|
of Common Stock |
$ |
1.98 |
$ |
1.48 |
||
Diluted Earnings per Share |
|
|
|
|
|
|
of Common Stock |
$ |
1.98 |
$ |
1.48 |
||
Weighted Average |
|
|
|
|
|
|
Number of Shares Outstanding |
|
|
|
|
|
|
For Basic Earnings Per Share |
|
893,416 |
|
893,416 |
||
Weighted Average |
|
|
|
|
|
|
Number of Shares Outstanding |
|
|
|
|
|
|
For Diluted Earnings Per Share |
|
894,030 |
|
893,648 |
||
For more detail related to the fiscal year 2021 unaudited first quarter results, please visit our web site at .
Statements herein that are not descriptions of historical facts are forward-looking and subject to risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors including risks relating to the ability to continue to extend current government contracts; the Company’s ability to obtain new government or commercial contracts; continued demand for the use of animal models in scientific research; the Company’s ability to perform under its contracts in accordance with the requirements of the contracts; the actual costs incurred in performing the Company’s contracts and its ability to manage its costs, including its capital expenditures; dependence on third parties; future capital needs; the ability to fund its capital needs through the use of its cash on hand and line of credit; and the future availability and cost of financing/capital sources to the Company.
View source version on businesswire.com:
